IL6 and Recurrent upper respiratory tract infections: For the first time, this study evaluated IL-6 in a broad collective of respiratory patients—from upper respiratory tract infection to pneumonia to sepsis with ARDS—including COVID-19 and non-COVID-19 regarding the degree of lung infiltrates.